Welcome!

Artificial Intelligence Authors: Liz McMillan, Zakia Bouachraoui, Pat Romanski, Yeshim Deniz, Elizabeth White

News Feed Item

Edwards Lifesciences Reports Strong First Quarter Sales and Earnings Growth

16 Percent Growth in Heart Valve Sales

IRVINE, CA -- (Marketwire) -- 04/27/09 -- Edwards Lifesciences Corporation (NYSE: EW), a world leader in products and technologies to treat advanced cardiovascular disease, today reported net income for the quarter ended March 31, 2009 of $60.5 million, or $1.03 per diluted share, compared to net income of $18.2 million, or $0.31 per diluted share, for the same period in 2008. Excluding special items detailed in the reconciliation table below, first quarter 2009 net income was $41.0 million, or $0.70 per diluted share, compared to net income of $33.2 million, or $0.56 per diluted share, for the same period last year. First quarter diluted earnings per share excluding special items increased 25 percent over last year.

First quarter net sales increased 5.6 percent to $313.5 million. Underlying(1) sales growth was 11.5 percent, which excludes a negative impact of $10.0 million from foreign exchange and $5.3 million from discontinued products.

"Our strong first quarter results were highlighted by robust heart valve sales and significant progress in bringing innovative products to clinicians and patients," said Michael A. Mussallem, Edwards Lifesciences' chairman and CEO. "Our earnings growth was achieved while increasing our investments in research and development by more than 20 percent in the quarter."

Sales Results

For the first quarter, the company reported Heart Valve Therapy sales of $170.4 million. Underlying growth of 20.3 percent over prior year excluded a $5.1 million negative impact from foreign exchange. Edwards SAPIEN transcatheter heart valves sales grew to $24.6 million.

"This quarter's sales growth was driven by momentum from our transcatheter heart valves in Europe and continued share gains in surgical heart valves," said Mussallem. "Based on our strong start, we now expect to achieve more than $100 million dollars in transcatheter heart valve sales this year. We are gratified that an increasing number of patients previously untreated by surgery have benefited from this technology."

Critical Care sales were $104.5 million for the quarter. Underlying growth of 1.7 percent over prior year excluded a $3.3 million reduction from foreign exchange. "Sales of new products, particularly our FloTrac disposables, continued to grow rapidly," said Mussallem. "This new product growth was substantially offset by lower hardware sales, reflecting restrained capital spending in U.S. hospitals."

"We expect several upcoming product introductions, including the expansion of FloTrac to the intensive care setting to elevate growth and we remain committed to our original goal of increasing Critical Care underlying sales growth by 6 to 9 percent for the year," added Mussallem.

Cardiac Surgery Systems sales for the quarter were $22.5 million. Underlying growth was 8.8 percent over prior year excluding foreign exchange, due primarily to growth of minimally invasive surgery products.

Vascular sales were $16.1 million, a decline from $22.0 million in the same quarter last year, due primarily to the divestiture of the LifeStent product line.

Domestic and international sales for the first quarter were $134.9 million and $178.6 million, respectively.

Additional Operating Results

For the quarter, Edwards' gross profit margin was 69.1 percent compared to 65.3 percent in the same period last year. This improvement was driven by a more profitable product mix and the favorable impact of foreign exchange hedge agreements, partially offset by Critical Care manufacturing variations.

Selling, general and administrative expenses were $121.9 million for the quarter, or 38.9 percent of sales, compared to $114.6 million in the prior year. The increase was due primarily to spending in Europe, the majority of which was for the Edwards SAPIEN transcatheter heart valve program, partially offset by foreign exchange.

Research and development expenses (R&D) for the quarter were $39.9 million, or 12.7 percent of sales. As a result of additional spending on transcatheter heart valve and glucose programs, R&D investments increased 21.3 percent compared to the prior year.

During the quarter, Edwards recorded a $30.8 million pre-tax special gain, including a $27.0 million milestone payment for the PMA approval specified in the LifeStent transaction, as detailed in the reconciliation tables below.

Free cash flow for the quarter was negative $8.1 million, calculated as cash used in operating activities of $36.0 million, minus capital expenditures of $11.1 million, plus a $39.0 million impact of terminating the company's Japan securitization program. For 2009, the company continues to expect free cash flow to be $160 to $170 million, excluding the impact of special items.

Total debt at March 31, 2009 was $123.0 million. Cash and cash equivalents were $146.7 million at the end of the quarter, resulting in net cash of $23.7 million.

During the quarter, the company repurchased 463,000 shares of common stock for $26.8 million.

2009 Outlook

"We expect this year's underlying sales growth to be between 10 to 12 percent and continue to project total sales at the upper end of our full year guidance of $1.24 billion to $1.30 billion," said Mussallem.

"Excluding special items, we estimate that second quarter 2009 diluted earnings per share will be between $0.73 and $0.77. For full year 2009, we are increasing the low end of our diluted earnings per share estimate by $0.02 to between $2.95 and $3.03, and we remain comfortable with our goal of increasing diluted earnings per share by 15 to 19 percent."

About Edwards Lifesciences

Edwards Lifesciences is the global leader in the science of heart valves and hemodynamic monitoring, with more than five decades of experience in partnering with clinicians to develop life-saving innovations. Headquartered in Irvine, Calif., Edwards treats advanced cardiovascular disease with its market-leading heart valve therapies, and critical care and vascular technologies, which are sold in approximately 100 countries. The company's global brands include Carpentier-Edwards, Cosgrove-Edwards, Edwards SAPIEN, FloTrac, Fogarty, PERIMOUNT Magna and Swan-Ganz. Additional company information can be found at http://www.edwards.com.

Conference Call and Webcast Information

Edwards Lifesciences will be hosting a conference call today at 5:00 p.m. ET to discuss its first quarter results. To participate in the conference call, dial (877) 407-8037 or (201) 689-8037. For 72 hours following the call, an audio replay can be accessed by dialing (877) 660-6853 or (201) 612-7415 and using account number 2995 and conference number 318217. The call will also be available via live or archived webcast on the "Investor Relations" section of Edwards' web site at www.edwards.com or www.edwards.com/InvestorRelations.

This news release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements can sometimes be identified by the use of words such as "may," "will," "should," "anticipate," "believe," "plan," "project," "estimate," "expect," "intend," or other similar expressions and include, but are not limited to, the company's financial goals or expectations for sales, gross profit margin improvement, net income, earnings per share and free cash flow; regulatory approval of new products in, and competitive dynamics associated with, the company's heart valve therapy product line; the continued adoption and sales of the FloTrac system; the timing and progress of clinical studies relating to the company's transcatheter valve technologies and the market opportunity for these products; and the impact of foreign exchange and special items on the company's results. Forward-looking statements are based on estimates and assumptions made by management of the company and are believed to be reasonable, though they are inherently uncertain and difficult to predict. Our forward-looking statements speak only as of the date on which they are made and we do not undertake any obligation to update any forward-looking statement to reflect events or circumstances after the date of the statement.

Forward-looking statements involve risks and uncertainties that could cause actual results or experience to differ materially from that expressed or implied by the forward-looking statements. Factors that could cause actual results or experience to differ materially from that expressed or implied by the forward-looking statements include the opportunities for the company's transcatheter valve programs and the ability of the company to continue to lead in the development of this field; the company's success in creating new market opportunities for its products and the timing of new product launches; the impact of currency exchange rates; the timing or results of pending or future clinical trials; actions by the U.S. Food and Drug Administration and other regulatory agencies; and other risks detailed in the company's filings with the Securities and Exchange Commission including its Annual Report on Form 10-K for the year ended December 31, 2008.

To supplement the consolidated financial results prepared in accordance with Generally Accepted Accounting Principles ("GAAP"), the company uses non-GAAP financial measures that exclude certain items, such as special charges and gains, results of discontinued and acquired product lines, and fluctuations in exchange rates. Management does not consider the excluded items part of day-to-day business or reflective of the core operational activities of the company as they result from transactions outside the ordinary course of business. Management uses non-GAAP financial measures internally for strategic decision making, forecasting future results and evaluating current performance. Certain guidance is provided on a non-GAAP (or "underlying") basis that excludes special items and foreign exchange fluctuations due to the inherent difficulty in forecasting such items. By disclosing non-GAAP financial measures, management intends to provide investors with a more meaningful, consistent comparison of the company's core operating results and trends for the periods presented. Non-GAAP financial measures are not prepared in accordance with GAAP; therefore, the information is not necessarily comparable to other companies and should be considered as a supplement to, not a substitute for, or superior to, the corresponding measures calculated in accordance with GAAP.

Edwards and Edwards dETlogix are trademarks of Edwards Lifesciences Corporation. Edwards Lifesciences, the stylized E logo, Carpentier-Edwards, Cosgrove-Edwards, Edwards SAPIEN, FloTrac, Fogarty, IMR ETlogix, Magna, PERIMOUNT Magna and Swan-Ganz are trademarks of Edwards Lifesciences Corporation and are registered in the United States Patent and Trademark Office.

(1) "Underlying" amounts are non-GAAP items and exclude discontinued and newly acquired products, and foreign exchange fluctuations. See the reconciliation table below.


EDWARDS LIFESCIENCES CORPORATION
Unaudited Consolidated Statements of Operations

                                                            Three Months
                                                                Ended
                                                              March 31,
(in millions, except per share data)                        2009     2008
                                                          -------  -------

Net sales                                                 $ 313.5  $ 296.8
Cost of goods sold                                           97.0    102.9
                                                          -------  -------

Gross profit                                                216.5    193.9

Selling, general and administrative expenses                121.9    114.6
Research and development expenses                            39.9     32.9
Special (gains) charges, net                                (30.8)    10.1
Interest expense, net                                         0.1      0.4
Other expense, net                                            0.4      1.2
                                                          -------  -------

Income before provision for income taxes                     85.0     34.7

Provision for income taxes                                   24.5     16.5
                                                          -------  -------

Net income                                                $  60.5  $  18.2
                                                          =======  =======

Earnings per share:
   Basic earnings per share                               $  1.08  $  0.32
   Diluted earnings per share                             $  1.03  $  0.31

Weighted average common shares outstanding:
   Basic                                                     56.0     56.1
   Diluted                                                   58.5     58.5

Operating Statistics
As a percentage of net sales:
   Gross profit                                              69.1%    65.3%
   Selling, general and administrative expenses              38.9%    38.6%
   Research and development expenses                         12.7%    11.1%
   Income before provision for income taxes                  27.1%    11.7%
   Net income                                                19.3%     6.1%

Effective tax rate                                           28.8%    47.6%
                                                          -------  -------

Computation of Diluted Earnings per Share
Net income                                                $  60.5  $  18.2
Adjustment for convertible debt interest expense                -      (A)
                                                          -------  -------
Adjusted net income                                       $  60.5  $  18.2
                                                          -------  -------

Weighted-average common shares outstanding
 used to calculate diluted earnings per share
 excluding convertible debt                                  58.5     58.5

Weighted-average common shares outstanding
 for the convertible debt                                       -      (A)
                                                          -------  -------

Weighted-average common shares outstanding
 used to calculate diluted earnings per share
 including the convertible debt                              58.5     58.5
                                                          -------  -------

Diluted earnings per share including the
 convertible debt                                         $  1.03  $  0.31
                                                          =======  =======

(A) The shares from the convertible debt have an anti-dilutive effect on
the earnings per share calculation in the first quarter of 2008. Therefore,
we have properly excluded both the shares and the related interest expense
from the diluted earnings per share calculation.  The convertible debt was
redeemed in June 2008.

Note: Numbers may not calculate due to rounding





EDWARDS LIFESCIENCES CORPORATION
Unaudited Balance Sheets
(in millions)

                                                        March    December
                                                         31,        31,
                                                        2009       2008
                                                      ---------  ---------
ASSETS

Current assets
Cash and cash equivalents                             $   146.7  $   218.7
Short-term investments                                      3.7        8.1
Accounts and other receivables, net                       255.8      204.7
Inventories, net                                          146.1      151.8
Deferred income taxes                                      35.6       42.4
Prepaid expenses                                           35.2       30.7
Other current assets                                       25.9       35.5
                                                      ---------  ---------
     Total current assets                                 649.0      691.9

Property, plant and equipment, net                        229.8      230.1
Goodwill                                                  315.7      315.7
Other intangible assets, net                               92.6       96.9
Investments in unconsolidated affiliates                   16.6       14.7
Deferred income taxes                                      36.9       37.7
Other assets                                               18.3       13.2
                                                      ---------  ---------

     Total assets                                     $ 1,358.9  $ 1,400.2
                                                      =========  =========

LIABILITIES AND STOCKHOLDERS' EQUITY

Accounts payable and accrued liabilities              $   200.2  $   258.5
Long-term debt                                            123.0      175.5
Other long-term liabilities                                92.4       87.4

Stockholders' equity
Common stock                                               74.3       73.7
Additional contributed capital                            969.0      940.4
Retained earnings                                         737.4      676.9
Accumulated other comprehensive loss                      (33.8)     (35.4)
Common stock in treasury, at cost                        (803.6)    (776.8)
                                                      ---------  ---------
     Total stockholders' equity                           943.3      878.8
                                                      ---------  ---------

Total liabilities and stockholders' equity            $ 1,358.9  $ 1,400.2
                                                      =========  =========


EDWARDS LIFESCIENCES CORPORATION

Non-GAAP Financial Information

To supplement the consolidated financial results prepared in accordance with Generally Accepted Accounting Principles ("GAAP"), the Company uses non-GAAP financial measures that exclude certain items such as special charges and gains, results of discontinued products, and fluctuations in exchange rates. Management does not consider the excluded items part of day-to-day business or reflective of the core operational activities of the Company as they result from transactions outside the ordinary course of business.

Management uses non-GAAP financial measures internally for strategic decision making, forecasting future results and evaluating current performance. Certain guidance is provided only on a non-GAAP (or "underlying") basis that excludes special items and foreign exchange fluctuations due to the inherent difficulty in forecasting such items. By disclosing non-GAAP financial measures, management intends to provide investors with a more meaningful, consistent comparison of the Company's core operating results and trends for the periods presented.

Non-GAAP financial measures are not prepared in accordance with GAAP; therefore, the information is not necessarily comparable to other companies and should be considered as a supplement to, not a substitute for, nor superior to, the corresponding measures calculated in accordance with GAAP.

The items described below are excluded from the GAAP financial results in the reconciliations that follow:

Special (gains) charges, net - The Company incurred certain special charges and gains in 2009 and 2008 related to the following:

   1) Milestone receipt and net loss on sale of assets:  $8.1 million net
      loss on the sale of the LifeStent product line in the first quarter
      of 2008;  $27.0 million gain in the first quarter of 2009 for
      achieving a milestone associated with the LifeStent PMA approval;

   2) Sale of distribution rights:  $2.8 million gain related to the sale
      of distribution rights in Europe of a specialty vascular graft in the
      first quarter of 2009;

   3) Reserve reversal:  $1.0 million gain in the first quarter of 2009
      resulting from completion of the Lifepath AAA clinical obligations;

   4) Litigation settlement:  $2.1 million charge for a litigation
      settlement in the first quarter of 2008;

   5) Realignment expenses, net:  $1.3 million charge for executive
      severance in the first quarter of 2008 associated with the Company's
      business realignment, offset by a $1.4 million gain in the first
      quarter of 2008 from the reversal of previously accrued severance
      costs from the fourth quarter of 2007 related to the sale of the
      LifeStent product line.

Given the magnitude and unusual nature of these special charges and gains relative to the operating results for the periods presented, these items have been excluded from non-GAAP net income.

Results of Discontinued and Other Products - The Company has discontinued certain products during the periods presented. As discontinued products do not have a continuing contribution to operations, management believes that excluding such items from the Company's sales growth provides investors with a means of evaluating the Company's on-going operations. In light of the significance of the impact these products had on the sales growth of the Company, the sales results of these products have been detailed in the "Unaudited Reconciliation of Sales by Product Line and Region."

Foreign Exchange - Fluctuation in exchange rates impacts the comparative results and sales growth rates of the Company's underlying business. Management believes that excluding the impact of foreign exchange rate fluctuations from its sales growth provides investors a more meaningful comparison to historical financial results. The impact of foreign exchange rate fluctuations has been detailed in the "Unaudited Reconciliation of Sales by Product Line and Region."




EDWARDS LIFESCIENCES CORPORATION
Reconciliation of GAAP to Non-GAAP Financial Information


                                                             Three Months
                                                                Ended
                                                              March 31,
(in millions, except per share data)                         2009    2008
                                                            ------  ------

GAAP net income                                             $ 60.5  $ 18.2

Reconciling items:

  Special (gains) charges, net
  1)  Milestone receipt and net loss on sale of assets       (27.0)    8.1
  2)  Sale of distribution rights                             (2.8)      -
  3)  Reserve reversal                                        (1.0)      -
  4)  Litigation settlement                                      -     2.1
  5)  Realignment expenses, net                                  -    (0.1)
                                                            ------  ------
    Total special (gains) charges, net                       (30.8)   10.1

  Provision for income taxes
    Tax effect on non-GAAP adjustments (A)                    11.3     4.9
                                                            ------  ------
    Total provision for income taxes, net                     11.3     4.9

                                                            ------  ------
Non-GAAP net income                                         $ 41.0  $ 33.2
                                                            ======  ======

Non-GAAP earnings per share:
Basic non-GAAP earnings per share                           $ 0.73  $ 0.59
Diluted non-GAAP earnings per share (B)                     $ 0.70  $ 0.56

Non-GAAP weighted average shares outstanding:
Basic                                                         56.0    56.1
Diluted                                                       58.5    61.2

                                                            ======  ======

Notes 1 - 5: See description of "Special (gains) charges, net" on the
previous page.

(A)  The tax effect on non-GAAP adjustments is calculated using the
relevant tax jurisdictions' statutory tax rates.
(B)  Diluted non-GAAP earnings per share for 2008 was calculated by adding
back to net income $1.0 million for the quarter in interest expense related
to previous convertible debt, then dividing by the weighted-average diluted
shares outstanding.  The convertible debt was redeemed in June 2008.

Note: Numbers may not calculate due to rounding





EDWARDS LIFESCIENCES CORPORATION
Unaudited Reconciliation of Sales by Product Line and Region
(in millions)


                                                          2009 Adjusted
                                                       --------------------
                                                     Discontinued/
                                                         Other
                                                GAAP    Product    1Q 2009
Sales by Product Line                          Growth    Line    Underlying
 (QTD)                 1Q 2009 1Q 2008 Change   Rate    Impact      Sales
                       ------- ------- ------  ------  ---------  ---------
Heart Valve Therapy    $ 170.4 $ 146.7 $ 23.7    16.2% $    (0.1)     170.3
Critical Care            104.5   106.7   (2.2)   (2.1%)        -      104.5
Cardiac Surgery
 Systems                  22.5    21.4    1.1     5.1%         -       22.5

Vascular                  16.1    22.0   (5.9)  (26.8%)     (3.0)      13.1
                       ------- ------- ------  ------  ---------  ---------
Total Sales            $ 313.5 $ 296.8 $ 16.7     5.6% $    (3.1) $   310.4
                       ------- ------- ------  ------  ---------  ---------



                               2008 Adjusted
                       ----------------------------
                     Discontinued/
                         Other
                        Product            1Q 2008  Underlying
Sales by Product Line    Line       FX   Underlying   Growth
 (QTD)                  Impact    Impact    Sales     Rate *
                       ---------  ------  --------- --------
Heart Valve Therapy    $       -  $ (5.1) $   141.6     20.3%
Critical Care               (0.6)   (3.3)     102.8      1.7%
Cardiac Surgery
 Systems                       -    (0.7)      20.7      8.8%
Vascular                    (7.8)   (0.9)      13.3     (2.5%)
                       ---------  ------  --------- --------

Total Sales            $    (8.4) $(10.0) $   278.4     11.5%
                       ---------  ------  --------- --------



                                                GAAP
                                               Growth
Sales by Region (QTD)  1Q 2009 1Q 2008 Change   Rate
                       ------- ------- ------  ------
United States          $ 134.9 $ 135.5 $ (0.6)   (0.4%)
                       ------- ------- ------  ------
   Europe                 98.8    91.2    7.6     8.3%
   Japan                  49.4    37.8   11.6    30.7%
   Rest of World          30.4    32.3   (1.9)   (5.9%)
                       ------- ------- ------  ------
International            178.6   161.3   17.3    10.7%
                       ------- ------- ------  ------
Total                  $ 313.5 $ 296.8 $ 16.7     5.6%
                       ------- ------- ------  ------

* Numbers may not calculate due to rounding.

Media Contact:
Amanda C. Fowler
949-250-5070

Investor Contact:
David K. Erickson
949-250-6826

More Stories By Marketwired .

Copyright © 2009 Marketwired. All rights reserved. All the news releases provided by Marketwired are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.

IoT & Smart Cities Stories
Dion Hinchcliffe is an internationally recognized digital expert, bestselling book author, frequent keynote speaker, analyst, futurist, and transformation expert based in Washington, DC. He is currently Chief Strategy Officer at the industry-leading digital strategy and online community solutions firm, 7Summits.
Digital Transformation is much more than a buzzword. The radical shift to digital mechanisms for almost every process is evident across all industries and verticals. This is often especially true in financial services, where the legacy environment is many times unable to keep up with the rapidly shifting demands of the consumer. The constant pressure to provide complete, omnichannel delivery of customer-facing solutions to meet both regulatory and customer demands is putting enormous pressure on...
IoT is rapidly becoming mainstream as more and more investments are made into the platforms and technology. As this movement continues to expand and gain momentum it creates a massive wall of noise that can be difficult to sift through. Unfortunately, this inevitably makes IoT less approachable for people to get started with and can hamper efforts to integrate this key technology into your own portfolio. There are so many connected products already in place today with many hundreds more on the h...
The standardization of container runtimes and images has sparked the creation of an almost overwhelming number of new open source projects that build on and otherwise work with these specifications. Of course, there's Kubernetes, which orchestrates and manages collections of containers. It was one of the first and best-known examples of projects that make containers truly useful for production use. However, more recently, the container ecosystem has truly exploded. A service mesh like Istio addr...
Digital Transformation: Preparing Cloud & IoT Security for the Age of Artificial Intelligence. As automation and artificial intelligence (AI) power solution development and delivery, many businesses need to build backend cloud capabilities. Well-poised organizations, marketing smart devices with AI and BlockChain capabilities prepare to refine compliance and regulatory capabilities in 2018. Volumes of health, financial, technical and privacy data, along with tightening compliance requirements by...
Charles Araujo is an industry analyst, internationally recognized authority on the Digital Enterprise and author of The Quantum Age of IT: Why Everything You Know About IT is About to Change. As Principal Analyst with Intellyx, he writes, speaks and advises organizations on how to navigate through this time of disruption. He is also the founder of The Institute for Digital Transformation and a sought after keynote speaker. He has been a regular contributor to both InformationWeek and CIO Insight...
Andrew Keys is Co-Founder of ConsenSys Enterprise. He comes to ConsenSys Enterprise with capital markets, technology and entrepreneurial experience. Previously, he worked for UBS investment bank in equities analysis. Later, he was responsible for the creation and distribution of life settlement products to hedge funds and investment banks. After, he co-founded a revenue cycle management company where he learned about Bitcoin and eventually Ethereal. Andrew's role at ConsenSys Enterprise is a mul...
To Really Work for Enterprises, MultiCloud Adoption Requires Far Better and Inclusive Cloud Monitoring and Cost Management … But How? Overwhelmingly, even as enterprises have adopted cloud computing and are expanding to multi-cloud computing, IT leaders remain concerned about how to monitor, manage and control costs across hybrid and multi-cloud deployments. It’s clear that traditional IT monitoring and management approaches, designed after all for on-premises data centers, are falling short in ...
In his general session at 19th Cloud Expo, Manish Dixit, VP of Product and Engineering at Dice, discussed how Dice leverages data insights and tools to help both tech professionals and recruiters better understand how skills relate to each other and which skills are in high demand using interactive visualizations and salary indicator tools to maximize earning potential. Manish Dixit is VP of Product and Engineering at Dice. As the leader of the Product, Engineering and Data Sciences team at D...
Dynatrace is an application performance management software company with products for the information technology departments and digital business owners of medium and large businesses. Building the Future of Monitoring with Artificial Intelligence. Today we can collect lots and lots of performance data. We build beautiful dashboards and even have fancy query languages to access and transform the data. Still performance data is a secret language only a couple of people understand. The more busine...